New injection targets tough leukemia in early trial
NCT ID NCT07246707
First seen Jan 11, 2026 · Last updated Jun 14, 2026 · Updated 26 times
Summary
This early-stage study is testing a new drug, KSV01, in 30 adults with B-cell acute lymphoblastic leukemia that has come back or not responded to standard treatments. The main goal is to check if the drug is safe and tolerable, and to find the right dose. Researchers will also look for early signs that the drug is working against the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-ALL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital of Zhejiang University
RECRUITINGHangzhou, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.